When.com Web Search

  1. Ad

    related to: lipitor liver damage lawsuit update

Search results

  1. Results From The WOW.Com Content Network
  2. Pfizer agrees to pay $93 million to settle Lipitor antitrust ...

    www.aol.com/news/pfizer-agrees-pay-93-million...

    Pfizer has agreed to pay $93 million to settle antitrust claims by wholesale drug distributors that accused it of conspiring with India's Ranbaxy Laboratories to delay sales of less expensive ...

  3. Fate of most remaining Zantac lawsuits weighed by ... - AOL

    www.aol.com/news/fate-most-remaining-zantac...

    Mark Cheffo, a lawyer for GSK, told Judge Vivian Medinilla of the Delaware Superior Court in Wilmington that the litigation was "a case of lawyers and lawsuits getting ahead of the science - way ...

  4. List of off-label promotion pharmaceutical settlements

    en.wikipedia.org/wiki/List_of_off-label...

    Franklin and his attorney, Thomas M. Greene, filed a lawsuit, Franklin v. Parke-Davis , under the False Claims Act in federal district court in Boston. In the first off-label promotion case ever litigated in a whistleblower suit under the False Claims Act, the settlement was announced after eight years of litigation in May 2004.

  5. Atorvastatin - Wikipedia

    en.wikipedia.org/wiki/Atorvastatin

    Liver impairment: Increased drug levels can be seen in people with advanced cirrhosis. [3] Despite these concerns, a 2017 systematic review and analysis of available evidence has shown that statins, such as atorvastatin, are relatively safe to use in stable, asymptomatic cirrhosis and may even reduce the risk of liver disease progression and death.

  6. Ezetimibe/atorvastatin - Wikipedia

    en.wikipedia.org/wiki/Ezetimibe/atorvastatin

    Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug.In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [1]

  7. UPDATE 6-Plaintiff in first Zantac lawsuit set for trial ...

    www.aol.com/news/1-plaintiff-first-zantac...

    Aug 17 (Reuters) - The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.

  8. Lipid-lowering agent - Wikipedia

    en.wikipedia.org/wiki/Lipid-lowering_agent

    Fibrates may decrease LDL, though generally to a lesser degree than statins. Similar to statins, the risk of muscle damage exists. Nicotinic acid, like fibrates, is also well suited for lowering triglycerides by 20–50%. It may also lower LDL by 5–25% and increase HDL by 15–35%. Niacin may cause hyperglycemia and may also cause liver damage.

  9. GSK whistleblower claims drugmaker cheated US government over ...

    www.aol.com/news/gsk-faces-whistleblower-lawsuit...

    The federal government declined to join the lawsuit in March, leaving Valisure to sue on its own. Zantac became the world's best selling medicine in 1988, and was one of the first drugs to top $1 ...